Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6)
Addiction2013Vol. 109(1), pp. 128–137
Citations Over TimeTop 10% of 2013 papers
Li‐Shiun Chen, A. Joseph Bloom, Timothy B. Baker, Stevens S. Smith, Megan E. Piper, Maribel Martínez, Nancy L. Saccone, Dorothy K. Hatsukami, Alison Goate, Laura J. Bierut
Abstract
Nicotine replacement therapy is effective among individuals with fast, but not slow, CYP2A6-defined nicotine metabolism. The effect of bupropion on relapse likelihood is unlikely to be affected by nicotine metabolism as estimated from CYP2A6 genotype. The variation in treatment responses among smokers with genes may guide future personalized smoking cessation interventions.
Related Papers
- → Smoking cessation treatment for COPD smokers: the role of pharmacological interventions(2015)11 cited
- → PRS4 EFFECTIVENESS OF VARENICLINE COMPARED TO BUPROPION AND NICOTINE REPLACEMENT THERAPY (NRT) FOR SMOKING CESSATION IN TWO SMOKING SPECIALIZED UNITS OF THE SPANISH PRIMARY CARE SETTING(2010)9 cited
- → Comparison of the Effectiveness of Varenicline, Extended-Release Bupropion and Nicotine Replacement Therapy on The Success and the Maintenance of a Smoking Cessation Program(2013)9 cited
- → Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials(2023)5 cited
- → A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline(2010)3 cited